crypto market means, See results about

Huadian energy: The subordinate power plants and holding companies received government subsidies of 22.33 million yuan. huadian energy announced that the subordinate power plants and holding companies of the company received government subsidies related to income of 22.33 million yuan on December 9, 2024. Among them, Harbin No.3 Power Plant of huadian energy Co., Ltd. received a government subsidy of 10.87 million yuan, and Harbin Thermal Power Co., Ltd. received a government subsidy of 11.46 million yuan. In accordance with the relevant provisions of Accounting Standards for Business Enterprises No.16-Government Subsidies, the company included this subsidy in the current profit and loss, and it is estimated that the total profit of the company in 2024 will be increased by 8.39 million yuan.Market information: Trump's nominee for finance minister, Bertrand Besson, said that Federal Reserve Chairman Powell can complete his remaining term.Nikkei futures opened down 95 points at 39,290 on the Singapore Stock Exchange.

Qujiang Wenlv: It received a warning letter from Shaanxi Supervision Bureau, and Qujiang Wenlv announced that the company received the Decision on Taking Measures to Issue Warning Letters to Xi 'an Qujiang Cultural Tourism Co., Ltd., Xie Xiaoning and Xi 'an Qujiang Tourism Investment Co., Ltd. issued by Shaanxi Supervision Bureau of China Securities Regulatory Commission on December 10, 2024. After investigation, the company delayed the disclosure of the major event that 8.23% of the company's shares held by the controlling shareholder Xi 'an Qujiang Tourism Investment Co., Ltd. were to be disposed of by the judiciary, which violated the relevant provisions of the Measures for the Administration of Information Disclosure of Listed Companies. According to Article 52 of the Measures, Shaanxi Supervision Bureau decided to take administrative supervision measures to issue warning letters to the company, Xie Xiaoning, the relevant responsible person, and Qujiang Travel Investment, the controlling shareholder. The company will seriously rectify, strengthen information disclosure and corporate governance, and improve the operation level and information disclosure quality.Eight-day four-board three-dimensional communication: the company's operation is normal, and the internal and external operating environment has not changed significantly. On December 9, December 10 and December 11, 2024, the company's closing price increase deviated by more than 20% for three consecutive trading days, which belongs to the abnormal fluctuation of stock trading. The company's operation is normal, and the internal and external operating environment has not changed significantly. The Company has no other circumstances that violate the provisions on fair disclosure of information.Oppenheimer: Raise the target price of opening customers from $980 to $1,075, and reiterate the rating of "outperforming the market".

Wells Fargo: Reduce the target price of Dow Chemical from $60 to $55, and maintain the "overweight" rating.Huadian energy: The subordinate power plants and holding companies received government subsidies of 22.33 million yuan. huadian energy announced that the subordinate power plants and holding companies of the company received government subsidies related to income of 22.33 million yuan on December 9, 2024. Among them, Harbin No.3 Power Plant of huadian energy Co., Ltd. received a government subsidy of 10.87 million yuan, and Harbin Thermal Power Co., Ltd. received a government subsidy of 11.46 million yuan. In accordance with the relevant provisions of Accounting Standards for Business Enterprises No.16-Government Subsidies, the company included this subsidy in the current profit and loss, and it is estimated that the total profit of the company in 2024 will be increased by 8.39 million yuan.Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.